Monitor for future disclosures of financial terms, revenue-sharing models, or milestone payments. The collaboration is strategic but lacks concrete near-term revenue impact. Watch for any subsequent 8-K or press release detailing commercial terms or product launch timelines.
Price Chart
Executive Summary
PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing with Verily's governed data and AI platform (Verily Pre). The partnership aims to create AI-ready clinico-genomic datasets at population scale, addressing a bottleneck in biomedical AI. No financial terms, revenue commitments, or specific milestones were disclosed, making this a non-binding strategic announcement.
Key Facts
- Multi-year strategic collaboration between PacBio and Verily Health announced
- Integration of PacBio HiFi sequencing with Verily Pre platform for AI-ready clinico-genomic datasets
- No financial terms, deal value, or revenue commitments disclosed
- Verily Pre Workbench already supports 20,000+ researchers and 700+ publications
- PacBio HiFi workflows already run end-to-end within Verily Pre environment
- Companies plan to expand integration to support large long-read programs across biopharma and population genomics
Financial Impact
No financial terms disclosed; non-binding collaboration with no stated revenue or milestone payments
Risk Factors
- No financial terms disclosed — partnership may not generate material near-term revenue
- Forward-looking statements subject to risks including technology development, competition, and regulatory issues
- Integration and scaling of long-read data with AI platform may face technical challenges
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383498 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.84 $2.27 | ▲ +23.10% | ▲ +23.24% | $2.25 (+22.28%) |
Oct 6, 2026 20d ago | 144 | $2.72 $1.99 | ▲ +26.84% | ▲ +25.86% | $2.25 (+17.28%) |
Oct 6, 2026 20d ago | Press Release | $2.70 $2.05 | ▼ −24.07% | ▼ −23.94% | $2.25 (−16.67%) |
Jun 4, 2026 20w ago | 8-K | $1.45 $1.31 | ▼ −9.66% | ▼ −10.22% | $2.25 (+55.17%) |
May 22, 2026 22w ago | DEFA14A | $1.26 $1.58 | ▲ +25.40% | ▲ +24.31% | $2.25 (+78.57%) |
Apr 21, 2026 26w ago | Press Release | $1.73 $1.58 | ▼ −8.67% | ▼ −9.75% | $2.25 (+30.06%) |
Apr 16, 2026 27w ago | Press Release | $1.69 $1.56 | ▼ −7.69% | ▼ −8.25% | $2.25 (+33.14%) |
Mar 5, 2026 33w ago | 8-K | $1.52 $1.27 | ▼ −16.45% | ▼ −14.21% | $2.25 (+48.03%) |
Mar 3, 2026 33w ago | Insider Cluster | $1.52 $1.37 | ▼ −9.87% | ▼ −9.39% | $2.25 (+48.03%) |
Feb 28, 2026 34w ago | Institutional Cluster | $1.62 $1.39 | ▼ −14.20% | ▼ −12.99% | $2.25 (+38.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers